The introduction of nicotinamide like a nicotine replacement in e-cigarette and smokeless products and solutions represents an important regulatory challenge for that FDA. Nicotinamide does not have nicotinic receptor agonist activity and is known to act as a sedative at substantial dosages6. The pr